Dr. Petrylak on FDA Approval of Pembrolizumab in Bladder Cancer

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with bladder cancer.

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with bladder cancer.

Related Content:

Yale Cancer CenterOncLive TVImmuno-OncologyGenitourinary CancersImmunotherapy in GU Cancers
Dr Saad on the Continued Investigation of Darolutamide Plus ADT in mHSPC
Dr Singhi on Identifying Care Gaps and Unmet Needs in Early-Stage Lung Cancer
Dr Wander on Limitations of First- and Later-Line Therapies in HR+ Breast Cancer